Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162430

SCHEMBL10162430

SCHEMBL10162430

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(Cl)c3)nc3ccnn23)cc1C

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 6/20 0.45
▸ MAPK1 P28482 7/20 0.43
▸ MMP8 P22894 2/20 0.43
▸ ADAMTS4 O75173 1/20 0.43
▸ MMP3 P08254 1/20 0.43
▸ MMP12 P39900 1/20 0.43
▸ PPARG P37231 3/20 0.42
▸ WDR5 P61964 3/20 0.41
▸ MMP10 P09238 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ DGAT1 O75907 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166079 0.93 MMP13 (0.46) MMP13MAPK1MMP8ADAMTS4MMP3
SCHEMBL10162426 0.93 MMP13 (0.53) MMP13MMP8ADAMTS4MMP3MMP12
SCHEMBL10162437 0.92 MMP13 (0.47) MMP13MMP8ADAMTS4MMP3MMP12
SCHEMBL10162467 0.90 MAPK1 (0.43) MMP13MAPK1PPARGWDR5DGAT1
SCHEMBL10162440 0.89 POLB (0.45) MMP13MMP8ADAMTS4MMP3MMP12
SCHEMBL10165461 0.89 MAPK1 (0.46) MMP13MAPK1PPARGWDR5DGAT1
SCHEMBL10165685 0.89 MAPK1 (0.46) MMP13MAPK1PPARGDGAT1
SCHEMBL8255680 0.88 MMP13 (0.41) MMP13MAPK1MMP8ADAMTS4MMP3
SCHEMBL10162418 0.87 MMP13 (0.50) MMP13MAPK1MMP8ADAMTS4MMP3
SCHEMBL8258270 0.86 MMP13 (0.61) MMP13MMP8ADAMTS4MMP3MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MAPK1 2860/4885MMP8 26/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885MAPK1 2860/4885MMP8 26/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MAPK1 2860/4885MMP8 26/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885MAPK1 2860/4885MMP8 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.